AU2007302256A1 - Directional use - Google Patents
Directional use Download PDFInfo
- Publication number
- AU2007302256A1 AU2007302256A1 AU2007302256A AU2007302256A AU2007302256A1 AU 2007302256 A1 AU2007302256 A1 AU 2007302256A1 AU 2007302256 A AU2007302256 A AU 2007302256A AU 2007302256 A AU2007302256 A AU 2007302256A AU 2007302256 A1 AU2007302256 A1 AU 2007302256A1
- Authority
- AU
- Australia
- Prior art keywords
- liquid
- nicotine
- active substance
- mouth
- directly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 104
- 239000007788 liquid Substances 0.000 claims description 104
- 229960002715 nicotine Drugs 0.000 claims description 90
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 89
- 239000000203 mixture Substances 0.000 claims description 73
- 210000000214 mouth Anatomy 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 67
- 239000013543 active substance Substances 0.000 claims description 63
- 239000007921 spray Substances 0.000 claims description 61
- 210000005179 oral vestibule Anatomy 0.000 claims description 42
- 238000005507 spraying Methods 0.000 claims description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 229920002678 cellulose Polymers 0.000 claims description 21
- 235000010980 cellulose Nutrition 0.000 claims description 20
- 238000010521 absorption reaction Methods 0.000 claims description 17
- 235000011187 glycerol Nutrition 0.000 claims description 16
- 239000001913 cellulose Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 12
- 230000009471 action Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 235000003599 food sweetener Nutrition 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 239000003765 sweetening agent Substances 0.000 claims description 8
- -1 gums Substances 0.000 claims description 7
- 239000006068 taste-masking agent Substances 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 4
- 229930013930 alkaloid Natural products 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- AIBWPBUAKCMKNS-PPHPATTJSA-N 2-hydroxybenzoic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)C1=CC=CC=C1O.CN1CCC[C@H]1C1=CC=CN=C1 AIBWPBUAKCMKNS-PPHPATTJSA-N 0.000 claims description 2
- MQWJVKLIBZWVEL-XRIOVQLTSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;dihydrochloride Chemical compound Cl.Cl.CN1CCC[C@H]1C1=CC=CN=C1 MQWJVKLIBZWVEL-XRIOVQLTSA-N 0.000 claims description 2
- HDJBTCAJIMNXEW-PPHPATTJSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;hydrochloride Chemical compound Cl.CN1CCC[C@H]1C1=CC=CN=C1 HDJBTCAJIMNXEW-PPHPATTJSA-N 0.000 claims description 2
- YHBIGBYIUMCLJS-UHFFFAOYSA-N 5-fluoro-1,3-benzothiazol-2-amine Chemical compound FC1=CC=C2SC(N)=NC2=C1 YHBIGBYIUMCLJS-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229940068917 polyethylene glycols Drugs 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- FGAFEHZTRRYNDF-UHFFFAOYSA-L zinc;3-(1-methylpyrrolidin-2-yl)pyridine;dichloride Chemical compound [Cl-].[Cl-].[Zn+2].CN1CCCC1C1=CC=CN=C1 FGAFEHZTRRYNDF-UHFFFAOYSA-L 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 description 15
- 229940087730 nicorette Drugs 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 11
- 235000019477 peppermint oil Nutrition 0.000 description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 10
- 235000019788 craving Nutrition 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000007937 lozenge Substances 0.000 description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 description 10
- 239000008108 microcrystalline cellulose Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 9
- 230000000391 smoking effect Effects 0.000 description 9
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 8
- 229940085605 saccharin sodium Drugs 0.000 description 8
- 239000000969 carrier Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 239000002612 dispersion medium Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000000779 smoke Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000008122 artificial sweetener Substances 0.000 description 3
- 235000021311 artificial sweeteners Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 241001478778 Cladophora Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 229920002488 Hemicellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001610364 Ovula Species 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 description 1
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- QLDPCHZQQIASHX-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.CN1CCCC1C1=CC=CN=C1 QLDPCHZQQIASHX-UHFFFAOYSA-N 0.000 description 1
- HXWLJBVVXXBZCM-UHFFFAOYSA-N 2,3-dihydroxypropyl nitrate Chemical class OCC(O)CO[N+]([O-])=O HXWLJBVVXXBZCM-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- IJVCSMSMFSCRME-UHFFFAOYSA-N 3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound C12CCC(O)C3OC4=C5C32CCN(C)C1CC5=CC=C4O IJVCSMSMFSCRME-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 206010059612 Tobacco withdrawal symptoms Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 229960002339 lobeline Drugs 0.000 description 1
- 229930013610 lobeline Natural products 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 229930013053 morphinan alkaloid Natural products 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000002643 mouth floor Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- LDMPZNTVIGIREC-ZGPNLCEMSA-N nicotine bitartrate Chemical compound O.O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 LDMPZNTVIGIREC-ZGPNLCEMSA-N 0.000 description 1
- 229940069688 nicotine bitartrate Drugs 0.000 description 1
- 229960001698 nicotine polacrilex Drugs 0.000 description 1
- 238000002670 nicotine replacement therapy Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- BRTHFWPGJMGHIV-UHFFFAOYSA-L zinc;3-(1-methylpyrrolidin-2-yl)pyridine;dichloride;hydrate Chemical compound O.[Cl-].[Cl-].[Zn+2].CN1CCCC1C1=CC=CN=C1 BRTHFWPGJMGHIV-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200601246 | 2006-09-27 | ||
| DKPA200601246 | 2006-09-27 | ||
| US95161907P | 2007-07-24 | 2007-07-24 | |
| US60/951,619 | 2007-07-24 | ||
| PCT/EP2007/008420 WO2008037470A1 (en) | 2006-09-27 | 2007-09-27 | Directional use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2007302256A1 true AU2007302256A1 (en) | 2008-04-03 |
Family
ID=38776389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007302256A Abandoned AU2007302256A1 (en) | 2006-09-27 | 2007-09-27 | Directional use |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10092715B2 (enExample) |
| EP (1) | EP2068982A1 (enExample) |
| JP (2) | JP2010504931A (enExample) |
| KR (1) | KR20090055606A (enExample) |
| CN (1) | CN101516426A (enExample) |
| AU (1) | AU2007302256A1 (enExample) |
| BR (1) | BRPI0716995A2 (enExample) |
| CA (1) | CA2660362C (enExample) |
| IL (1) | IL197573A0 (enExample) |
| MX (1) | MX2009001865A (enExample) |
| NO (1) | NO20091345L (enExample) |
| RU (1) | RU2009115720A (enExample) |
| WO (1) | WO2008037470A1 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| JP6250262B2 (ja) * | 2009-02-09 | 2017-12-20 | セルテック・アクチボラゲットＣｅｌｌｕｔｅｃｈ Ａｂ | ポリマーシェル |
| US20110268809A1 (en) | 2010-04-28 | 2011-11-03 | Paul Andrew Brinkley | Nicotine-Containing Pharmaceutical Compositions |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| JP5681819B2 (ja) | 2011-02-11 | 2015-03-11 | バットマーク・リミテッド | 吸入器コンポーネント |
| AT510837B1 (de) | 2011-07-27 | 2012-07-15 | Helmut Dr Buchberger | Inhalatorkomponente |
| WO2013034459A1 (en) | 2011-09-06 | 2013-03-14 | British American Tobacco (Investments) Limited | Heating smokeable material |
| JP6017562B2 (ja) | 2011-09-06 | 2016-11-02 | ブリティッシュ アメリカン タバコ （インヴェストメンツ） リミテッドＢｒｉｔｉｓｈ Ａｍｅｒｉｃａｎ Ｔｏｂａｃｃｏ （Ｉｎｖｅｓｔｍｅｎｔｓ） Ｌｉｍｉｔｅｄ | 喫煙材の加熱 |
| US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
| US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
| AT511344B1 (de) | 2011-10-21 | 2012-11-15 | Helmut Dr Buchberger | Inhalatorkomponente |
| GB201207039D0 (en) | 2012-04-23 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
| GB2504075A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
| GB2504076A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
| USD732659S1 (en) | 2013-03-26 | 2015-06-23 | Pediatric Innovations USA, LLC | Car-shaped nasal device |
| USD732658S1 (en) | 2013-03-26 | 2015-06-23 | Pediatric Innovations USA, LLC | Nasal device with airplane wings |
| USD701956S1 (en) * | 2013-03-26 | 2014-04-01 | Pediatric Innovations USA, LLC | Nasal device |
| USD701599S1 (en) * | 2013-03-26 | 2014-03-25 | Pediatric Innovations USA, LLC | Nasal device |
| GB2513637A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
| GB2513639A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
| GB2514893B (en) | 2013-06-04 | 2017-12-06 | Nicoventures Holdings Ltd | Container |
| GB201407426D0 (en) | 2014-04-28 | 2014-06-11 | Batmark Ltd | Aerosol forming component |
| GB2528673B (en) | 2014-07-25 | 2020-07-01 | Nicoventures Holdings Ltd | Aerosol provision system |
| GB2533135B (en) | 2014-12-11 | 2020-11-11 | Nicoventures Holdings Ltd | Aerosol provision systems |
| GB201505597D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Article for use with apparatus for heating smokable material |
| GB201505595D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Cartridge for use with apparatus for heating smokeable material |
| GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
| GB201511361D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic vapour provision system |
| US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
| US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
| GB201516729D0 (en) * | 2015-09-22 | 2015-11-04 | The Technology Partnership Plc | Liquid nicotine formulation |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
| US10532046B2 (en) | 2015-12-03 | 2020-01-14 | Niconovum Usa, Inc. | Multi-phase delivery compositions and products incorporating such compositions |
| US20170165252A1 (en) | 2015-12-10 | 2017-06-15 | Niconovum Usa Inc. | Protein-enriched therapeutic composition |
| EP4706709A3 (en) | 2016-04-27 | 2026-05-20 | Nicoventures Trading Ltd | ELECTRONIC AEROSOL SUPPLY SYSTEM AND ASSOCIATED SPRAYER |
| EP3558267B1 (en) * | 2016-12-20 | 2023-04-26 | Fertin Pharma A/S | A mucoadhesive oromucosal formulation comprising a nicotine complex |
| EP3906916A1 (en) | 2017-12-08 | 2021-11-10 | Fertin Pharma A/S | Nicotine tablet |
| EP3720497A1 (en) | 2017-12-08 | 2020-10-14 | Fertin Pharma A/S | High nicotine concentration |
| CA3085064C (en) * | 2017-12-08 | 2023-10-24 | Fertin Pharma A/S | Nicotine mouth spray |
| EP3807260B1 (en) | 2018-06-15 | 2024-09-18 | R. J. Reynolds Tobacco Company | Purification of nicotine |
| JP6676805B2 (ja) * | 2018-07-12 | 2020-04-08 | 株式会社 東亜産業 | 芳香カートリッジ用充填物、それを有する芳香カートリッジ用エアロゾル形成基材およびそれを有する芳香カートリッジ |
| JP7528084B2 (ja) * | 2018-12-28 | 2024-08-05 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | 金属塩を含むニコチン製剤 |
| CN112384088B (zh) | 2019-05-21 | 2024-05-14 | 未来科技株式会社 | 受热芳香发生体、芳香烟弹以及受热芳香发生体的制造方法和制造装置 |
| US12342847B2 (en) | 2019-09-11 | 2025-07-01 | Nicoventures Trading Limited | Oral product with cellulosic flavor stabilizer |
| US12213510B2 (en) | 2019-09-11 | 2025-02-04 | Nicoventures Trading Limited | Pouched products with enhanced flavor stability |
| CN110558605B (zh) * | 2019-09-27 | 2021-07-06 | 深圳雾芯科技有限公司 | 电子烟液 |
| US11889856B2 (en) | 2019-12-09 | 2024-02-06 | Nicoventures Trading Limited | Oral foam composition |
| US12151023B2 (en) | 2019-12-09 | 2024-11-26 | Nicoventures Trading Limited | Oral composition with beet material |
| US11969502B2 (en) | 2019-12-09 | 2024-04-30 | Nicoventures Trading Limited | Oral products |
| US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
| US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
| US12520867B2 (en) | 2019-12-09 | 2026-01-13 | Nicoventures Trading Limited | Buffered oral compositions |
| US12310959B2 (en) | 2019-12-09 | 2025-05-27 | Nicoventures Trading Limited | Oral compositions with reduced water content |
| US12171872B2 (en) | 2019-12-09 | 2024-12-24 | Nicoventures Trading Limited | Oral compositions and methods of manufacture |
| US12599160B2 (en) | 2019-12-09 | 2026-04-14 | Nicoventures Trading Limited | Lipid-containing oral composition |
| US12439949B2 (en) | 2019-12-09 | 2025-10-14 | Nicoventures Trading Limited | Oral compositions with reduced water activity |
| US12491250B2 (en) | 2019-12-09 | 2025-12-09 | Nicoventures Trading Limited | Oral composition with nanocrystalline cellulose |
| US11617744B2 (en) | 2019-12-09 | 2023-04-04 | Nico Ventures Trading Limited | Moist oral compositions |
| US11826462B2 (en) | 2019-12-09 | 2023-11-28 | Nicoventures Trading Limited | Oral product with sustained flavor release |
| US12433321B2 (en) | 2019-12-09 | 2025-10-07 | Nicoventures Trading Limited | Oral composition with beet material |
| US12550928B2 (en) | 2019-12-09 | 2026-02-17 | Nicoventures Trading Limited | Liquid oral composition |
| US12439952B2 (en) | 2019-12-09 | 2025-10-14 | Nicoventures Trading Limited | Moist oral compositions |
| JP2023504756A (ja) | 2019-12-09 | 2023-02-06 | ニコベンチャーズ トレーディング リミテッド | カンナビノイドを含む口腔用製品 |
| US11883527B2 (en) | 2019-12-09 | 2024-01-30 | Nicoventures Trading Limited | Oral composition and method of manufacture |
| US12137723B2 (en) | 2019-12-09 | 2024-11-12 | Nicoventures Trading Limited | Oral products with active ingredient combinations |
| JP2023505351A (ja) | 2019-12-09 | 2023-02-08 | ニコベンチャーズ トレーディング リミテッド | 口腔用組成物のための薬剤 |
| US11672862B2 (en) | 2019-12-09 | 2023-06-13 | Nicoventures Trading Limited | Oral products with reduced irritation |
| EP4161295A1 (en) | 2020-06-08 | 2023-04-12 | Nicoventures Trading Limited | Effervescent oral composition comprising an active ingredient |
| US11839602B2 (en) | 2020-11-25 | 2023-12-12 | Nicoventures Trading Limited | Oral cannabinoid product with lipid component |
| WO2022261552A1 (en) * | 2021-06-11 | 2022-12-15 | Boa Nutrition, Inc. | Nozzle with fan for delivering aerosols |
| WO2022269556A1 (en) | 2021-06-25 | 2022-12-29 | Nicoventures Trading Limited | Oral products and method of manufacture |
| CN119789793A (zh) | 2021-07-30 | 2025-04-08 | 尼科凡图尔斯贸易有限公司 | 包含微晶纤维素的气溶胶发生基材 |
| EP4408183A1 (en) | 2021-09-30 | 2024-08-07 | Nicoventures Trading Limited | Oral product with a basic amine and an ion pairing agent |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2619718B1 (fr) * | 1987-09-02 | 1991-07-12 | Medibrevex | Nouvelles formes galeniques de beta-2-mimetiques pour administration par voie per- et sublinguale |
| GB8828468D0 (en) | 1988-12-06 | 1989-01-05 | Stoppers Co Ltd | Nicotine containing lozenge |
| US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| US5362496A (en) | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| IT233948Y1 (it) | 1994-07-20 | 2000-02-16 | Plastiape Spa | Dispositivo erogatore tascabile,particolrmente studiato per immettere nel cavo orale sostanze medicamentose nebulizzate |
| US5955098A (en) * | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
| FI974578A7 (fi) * | 1997-12-19 | 1999-06-20 | Orion Yhtymae Oyj | Menetelmä levosimendaanin antamiseksi |
| US5981499A (en) * | 1998-02-20 | 1999-11-09 | Atlantic Biomed Corporation | Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa |
| US6080783A (en) * | 1998-09-01 | 2000-06-27 | Gum Tech International, Inc. | Method and composition for delivering zinc to the nasal membrane |
| EP1139773A4 (en) | 1998-12-15 | 2002-06-12 | Wrigley W M Jun Co | CONTROLLED DELIVERY OF ACTIVE SUBSTANCES FROM A CHEWING GUM COATING |
| US6799576B2 (en) * | 1999-07-16 | 2004-10-05 | Aradigm Corporation | System for effecting smoking cessation |
| BR0108730A (pt) * | 2000-02-28 | 2002-11-05 | Vectura Ltd | Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados |
| SE0003665D0 (sv) * | 2000-10-11 | 2000-10-11 | Astrazeneca Ab | A delivery device |
| AU2002231970B2 (en) * | 2001-02-14 | 2007-08-16 | CNX Therapeutics Limited | Mucoadhesive pharmaceutical formulations |
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| US20040037879A1 (en) * | 2001-11-02 | 2004-02-26 | Adusumilli Prasad S. | Oral controlled release forms useful for reducing or preventing nicotine cravings |
| SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| DK1803443T3 (en) * | 2002-12-20 | 2019-02-25 | Niconovum Ab | Nicotine-containing particulate material with a crystalline cellulose |
| SI1617823T1 (sl) | 2003-01-24 | 2019-07-31 | Nicachet Ab | Vrečka, ki obsega nikotinski sestavek za transmukozno dajanje |
| GB0305581D0 (en) * | 2003-03-11 | 2003-04-16 | Dallas Burston Ltd | Dispensing devices |
| US20050150489A1 (en) * | 2004-01-12 | 2005-07-14 | Steve Dunfield | Dispensing medicaments based on rates of medicament action |
| NZ551336A (en) * | 2004-04-22 | 2010-04-30 | Acucort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
| JP2008540034A (ja) * | 2005-05-18 | 2008-11-20 | ザ ジーアイ カンパニー インコーポレーティッド | 経口薬物送達システムおよびその使用方法 |
-
2007
- 2007-09-27 RU RU2009115720/14A patent/RU2009115720A/ru unknown
- 2007-09-27 EP EP07818503A patent/EP2068982A1/en not_active Withdrawn
- 2007-09-27 BR BRPI0716995-7A patent/BRPI0716995A2/pt not_active Application Discontinuation
- 2007-09-27 CN CNA2007800361099A patent/CN101516426A/zh active Pending
- 2007-09-27 WO PCT/EP2007/008420 patent/WO2008037470A1/en not_active Ceased
- 2007-09-27 JP JP2009529608A patent/JP2010504931A/ja active Pending
- 2007-09-27 AU AU2007302256A patent/AU2007302256A1/en not_active Abandoned
- 2007-09-27 MX MX2009001865A patent/MX2009001865A/es not_active Application Discontinuation
- 2007-09-27 KR KR1020097006341A patent/KR20090055606A/ko not_active Ceased
- 2007-09-27 CA CA2660362A patent/CA2660362C/en active Active
- 2007-09-27 US US12/440,817 patent/US10092715B2/en active Active
-
2009
- 2009-03-12 IL IL197573A patent/IL197573A0/en unknown
- 2009-04-01 NO NO20091345A patent/NO20091345L/no not_active Application Discontinuation
-
2013
- 2013-11-08 JP JP2013232105A patent/JP2014076370A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101516426A (zh) | 2009-08-26 |
| NO20091345L (no) | 2009-04-01 |
| RU2009115720A (ru) | 2010-11-10 |
| MX2009001865A (es) | 2009-04-07 |
| US10092715B2 (en) | 2018-10-09 |
| WO2008037470A1 (en) | 2008-04-03 |
| KR20090055606A (ko) | 2009-06-02 |
| CA2660362C (en) | 2018-03-20 |
| US20100108059A1 (en) | 2010-05-06 |
| IL197573A0 (en) | 2009-12-24 |
| JP2014076370A (ja) | 2014-05-01 |
| EP2068982A1 (en) | 2009-06-17 |
| JP2010504931A (ja) | 2010-02-18 |
| CA2660362A1 (en) | 2008-04-03 |
| BRPI0716995A2 (pt) | 2013-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2660362C (en) | Use of a device or spray apparatus for oral administration of a liquid containing an active substance for improved absorption | |
| RU2279871C2 (ru) | Жидкая фармацевтическая композиция, содержащая никотин, для введения в полость рта | |
| US20090023819A1 (en) | Use of an Artificial Sweetener to Enhance Absorption of Nicotine | |
| EP1509227B1 (en) | A buffered, liquid nicotine composition for pulmonary administration | |
| US7767698B2 (en) | Formulation and use thereof | |
| JP6169609B2 (ja) | 感覚刺激性撹乱の低減された固体ニコチン含有剤形 | |
| CN102770138B (zh) | 含有尼古丁的软凝胶锭剂 | |
| US20030159702A1 (en) | Formulation and use manufacture thereof | |
| US20080138399A1 (en) | Dual release nicotine formulations, and systems and methods for their use | |
| US20080138398A1 (en) | Dual release nicotine formulations, and systems and methods for their use | |
| Chauhan et al. | Nicotine replacement therapy for smoking cessation | |
| ZA200601949B (en) | Nicotine formulations and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |